Comprehensive proteomic analysis and multidimensional model construction of peritoneal metastasis in gastric cancer
Cancer Letters,
Год журнала:
2025,
Номер
unknown, С. 217509 - 217509
Опубликована: Фев. 1, 2025
Язык: Английский
Nanocarriers for cutting-edge cancer immunotherapies
Journal of Translational Medicine,
Год журнала:
2025,
Номер
23(1)
Опубликована: Апрель 15, 2025
Cancer
immunotherapy
aims
to
harness
the
body's
own
immune
system
for
effective
and
long-lasting
elimination
of
malignant
neoplastic
tissues.
Owing
advance
in
understanding
cancer
pathology
immunology,
many
novel
strategies
enhancing
immunological
responses
against
various
cancers
have
been
successfully
developed,
some
translated
into
excellent
clinical
outcomes.
As
one
promising
strategy
next
generation
immunotherapies,
activating
multi-cellular
network
(MCN)
within
tumor
microenvironment
(TME)
deploy
multiple
mechanisms
action
(MOAs)
has
attracted
significant
attention.
To
achieve
this
effectively
safely,
delivering
or
pleiotropic
therapeutic
cargoes
targeted
sites
cancerous
tissues,
cells,
intracellular
organelles
is
critical,
which
numerous
nanocarriers
developed
leveraged.
In
review,
we
first
introduce
payloads
categorized
according
their
predicted
functions
physicochemical
structures
forms.
Then,
nanocarriers,
along
with
unique
characteristics,
properties,
advantages,
limitations,
are
introduced
notable
recent
applications
immunotherapy.
Following
discussions
on
targeting
strategies,
a
summary
each
nanocarrier
matching
suitable
provided
comprehensive
background
information
designing
regimens.
Язык: Английский
Regulation of the CD8⁺ T Cell and PDL1/PD1 Axis in Gastric Cancer: Unraveling the Molecular Landscape
Critical Reviews in Oncology/Hematology,
Год журнала:
2025,
Номер
unknown, С. 104750 - 104750
Опубликована: Апрель 1, 2025
Язык: Английский
Nanomedicine for cancer patient‐centered care
MedComm,
Год журнала:
2024,
Номер
5(11)
Опубликована: Окт. 20, 2024
Abstract
Cancer
is
a
leading
cause
of
morbidity
and
mortality
worldwide,
an
increase
in
incidence
estimated
the
next
future,
due
to
population
aging,
which
requires
development
highly
tolerable
low‐toxicity
cancer
treatment
strategies.
The
use
nanotechnology
tailor
treatments
according
genetic
immunophenotypic
characteristics
patient's
tumor,
allow
its
targeted
release,
can
meet
this
need,
improving
efficacy
minimizing
side
effects.
Nanomedicine‐based
approach
for
diagnosis
rapidly
evolving
field.
Several
nanoformulations
are
currently
clinical
trials,
some
have
been
approved
marketed.
However,
their
large‐scale
production
still
hindered
by
in‐depth
debate
involving
ethics,
intellectual
property,
safety
health
concerns,
technical
issues,
costs.
Here,
we
survey
key
approaches,
with
specific
reference
organ‐on
chip
technology,
cutting‐edge
tools,
such
as
CRISPR/Cas9
genome
editing,
through
nanosystems
needs
personalized
diagnostics
therapy
patients.
An
update
provided
on
nanopharmaceuticals
marketed
those
undergoing
trials.
Finally,
discuss
emerging
avenues
field
challenges
be
overcome
transfer
nano‐based
precision
oncology
into
daily
life.
Язык: Английский